Last reviewed · How we verify

Nguyen Viet Giap — Portfolio Competitive Intelligence Brief

Nguyen Viet Giap pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cationorm single-dose eye drop Cationorm single-dose eye drop marketed Artificial tear / ocular lubricant Ophthalmology
Artificial tear eye drop Artificial tear eye drop marketed Ophthalmic lubricant Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 2 shared drug classes
  2. Bausch & Lomb Incorporated · 1 shared drug class
  3. Chang Gung Memorial Hospital · 1 shared drug class
  4. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
  5. Massachusetts Eye and Ear Infirmary · 1 shared drug class
  6. Medical University of Vienna · 1 shared drug class
  7. National University of Malaysia · 1 shared drug class
  8. ORA, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nguyen Viet Giap:

Cite this brief

Drug Landscape (2026). Nguyen Viet Giap — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nguyen-viet-giap. Accessed 2026-05-16.

Related